A randomised, double blind, placebo controlled, multi center, parallel group, dose finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52 weeks on physical function, muscle....

Project Details

Short titleR:KBD A randomised, double bli
Effective start/end date12/09/1420/07/16

Collaborative partners


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.